<DOC>
	<DOCNO>NCT02822326</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy chimeric antigen receptor 19 ( CD19-CAR-T2 Cells ) infusion patient chemotherapy resistant refractory CD19+ acute Leukemia .</brief_summary>
	<brief_title>Phase I Study CD19-CAR-T2 Cells Patients With Chemotherapy Resistant Refractory CD19+ Acute Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<criteria>Patient relapse and/or refractory CD19 positive Bcell acute leukemia Eastern Cooperative Oncology Group ( ECOG ) performance status 《 3 ALT/ AST 《 3x normal Bilirubin &lt; 2.0 mg/dl Creatinine &lt; 2.5 mg/dl less 2.5x normal age LVEF》 45 % Accept white blood cell collection Provide inform consent Previous treatment investigational gene cell therapy medicine product Solitary extramedullary relapse Active hepatitis B , hepatitis C HIV infection Uncontrolled active infection Presence grade 24 acute extensive chronic GVHD Active CNS involvement : epilepsy , paresis , aphasia , stroke , severe head trauma , Dementia , Parkinson 's disease , cerebellar disease , organic brain syndrome , uncontrolled mental illness , etc . Any uncontrolled active medical disorder would preclude participation outline . Received nondiagnostic purpose major surgery within past 4 week Participated clinical study within past 4 week Used murine biological product ( except blinatumomab ) , unless prove antimouse antibody exist . Pregnancy breastfeed woman Use prohibit drug : Steroids : Therapeutic dos steroid must stop &gt; 72 hour prior CD19CART2 Cells infusion Allogeneic cellular therapy : Any donor lymphocyte infusion ( DLI ) must complete &gt; 4 week prior CD19CART2 Cells infusion GVHD therapy : Any drug use GVHD must stop &gt; 4 week prior CD19CART2 Cells infusion Chemotherapy : . The following drug must stop &gt; 1 week prior CTL019 infusion administer concomitantly follow lymphodepleting chemotherapy : hydroxyurea , vincristine , 6mercaptopurine , 6thioguanine , methotrexate &lt; 25 mg/m2 , cytosine arabinoside &lt; 10 mg/m2/day , asparaginase ; ii . The following drug must stop &gt; 4 week prior CTL019 infusion : salvage chemotherapy ( e.g . clofarabine , cytosine arabinoside &gt; 100 mg/m2 , anthracyclines , cyclophosphamide ) , exclude require lymphodepleting chemotherapy drug Any situation may increase risk test interfere test result</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>CART CD19</keyword>
	<keyword>Chemotherapy Resistant</keyword>
	<keyword>Chemotherapy Refractory</keyword>
	<keyword>CD19 +</keyword>
	<keyword>Lymphoma</keyword>
</DOC>